This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| trastuzumab emtansine | |
|---|---|
| Name | Trastuzumab emtansine |
| Tradename | Kadcyla |
| Routes of administration | Intravenous |
| Atc prefix | L01 |
| Atc suffix | XC90 |
| Legal status | Prescription-only |
trastuzumab emtansine is an antibody–drug conjugate indicated for HER2-positive breast cancer and related malignancies. Developed by collaboration between Genentech, Roche, and subsidiary partners, it combines a monoclonal antibody targeting Human epidermal growth factor receptor 2 with a cytotoxic microtubule inhibitor to deliver targeted chemotherapy. The agent is used in metastatic and adjuvant settings following prior therapies, and its development involved major oncology trials and regulatory reviews by agencies such as the United States Food and Drug Administration and the European Medicines Agency.
Trastuzumab emtansine is approved for treatment of HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, and for residual invasive disease after neoadjuvant therapy in early-stage disease, reflecting recommendations from bodies such as the National Comprehensive Cancer Network and guidance from the American Society of Clinical Oncology. Clinicians consider prior exposure to agents like docetaxel, paclitaxel, and trastuzumab when selecting therapy; multidisciplinary tumor boards at institutions such as the Memorial Sloan Kettering Cancer Center and Mayo Clinic often weigh benefits against cardiotoxicity risks known from HER2-directed agents described by cardiology groups including the American College of Cardiology. Off-label and investigational uses have been explored in HER2-positive gastric cancer, HER2-mutant non-small cell lung cancer, and other solid tumors in trials run by centers including Dana–Farber Cancer Institute and Johns Hopkins Hospital.
As an antibody–drug conjugate, the agent links a humanized IgG1 monoclonal antibody derived from trastuzumab to a microtubule inhibitor payload via a stable linker; pharmacokinetic profiles were characterized in pharmacology studies reported by research groups at Stanford University, University of California, San Francisco, and academic collaborators. Distribution is influenced by HER2 expression in tumor tissue and off-target uptake in organs monitored by investigators at Mayo Clinic and Massachusetts General Hospital. Metabolism involves lysosomal degradation pathways described in translational work from laboratories such as MIT and Harvard Medical School, and elimination parameters were evaluated in population PK analyses conducted by teams affiliated with Genentech and regulatory reviewers at the FDA.
Pivotal randomized trials such as those led by cooperative groups and sponsored by industry compared the agent to standard regimens including capecitabine plus lapatinib and physician's choice therapies; landmark studies were presented at meetings of the American Society of Clinical Oncology and European Society for Medical Oncology. Key trials reported improved progression-free survival and overall survival endpoints with statistical analyses overseen by independent data monitoring committees and academic statisticians from institutions like Memorial Sloan Kettering Cancer Center and Dana–Farber Cancer Institute. Subsequent subgroup and biomarker analyses involved collaborators at MD Anderson Cancer Center, King's College London, and European centers that contributed to pooled meta-analyses informing guidelines from NICE and consensus statements by professional societies including the European Society for Medical Oncology.
Safety profiles identified thrombocytopenia, elevated hepatic transaminases, and potential cardiotoxicity—concerns also seen with HER2-targeted therapies referenced by cardiology groups such as the European Society of Cardiology. Post-marketing surveillance conducted by regulators at the FDA and EMA and pharmacovigilance units at Roche documented rare events including interstitial lung disease and infusion-related reactions; multidisciplinary care involving pulmonologists from centers like Cleveland Clinic and hepatologists at Johns Hopkins Hospital informs management. Safety monitoring integrates recommendations from oncology organizations such as the American Society of Clinical Oncology and nursing protocols developed by institutions including Memorial Sloan Kettering Cancer Center.
The agent is administered intravenously at weight-based dosing intervals determined in registration studies run by Genentech and clinical trial groups; infusion protocols and dose modifications for adverse events are detailed in prescribing information approved by the US FDA and the European Commission. Administration takes place in oncology infusion centers affiliated with hospitals such as Mayo Clinic and Massachusetts General Hospital, with premedication and monitoring guided by standards from the American Society of Clinical Oncology and nursing practice recommendations from organizations like the Oncology Nursing Society. Dose adjustments for hepatic impairment and thrombocytopenia follow criteria developed through clinical pharmacology consultations led by academic investigators at UCSF and Stanford University.
Chemically, the drug conjugates the monoclonal antibody to a derivative of maytansine via a non-reducible linker developed through med-chem collaborations between researchers at Genentech, Roche, and academic chemistry groups such as those at MIT and ETH Zurich. The HER2-targeting antibody binds the extracellular domain of the receptor, promoting internalization and lysosomal processing, after which the cytotoxic payload inhibits microtubule assembly, a mechanism studied in basic science laboratories including Cold Spring Harbor Laboratory and Salk Institute for Biological Studies. Structure–activity studies and mass spectrometry characterizations were performed by analytical teams at GlaxoSmithKline-level facilities and university core labs including University of Cambridge and University of Oxford.
Regulatory approvals were granted following review by agencies including the US Food and Drug Administration and the European Medicines Agency, based on phase III data submitted by Genentech/Roche. Commercialisation strategies involved licensing, manufacturing scale-up in facilities comparable to those operated by multinational pharmaceutical companies such as Novartis and Pfizer, and distribution through oncology supply chains coordinated with hospital systems like Kaiser Permanente and oncology pharmacy services at Mayo Clinic. Pricing, reimbursement, and access discussions have engaged payers including Centers for Medicare & Medicaid Services and health technology assessment agencies such as NICE.
Category:Antineoplastic drugs